Arthritis

Arthritis in Primary Care: Scope and Clinical Significance

Arthritis is one of the most common chronic conditions encountered in primary care, particularly among older adults. It encompasses a group of inflammatory and degenerative joint disorders that cause pain, stiffness, swelling, and reduced mobility. For the Family Nurse Practitioner (FNP), accurate diagnosis and evidence-based management of arthritis are essential to preserve function, control symptoms, and prevent long-term disability. Approximately 1 in 4 US adults (about 58.5 million people) have arthritis, and the prevalence increases with age ^[1]. High-yield topics on the FNP exam include distinguishing osteoarthritis (OA) from rheumatoid arthritis (RA), appropriate pharmacologic and non-pharmacologic treatments, and recognition of red flags that require specialist referral.

Arthritis Subtypes: Pathophysiology and Clinical Distinctions

• Osteoarthritis (OA): A degenerative joint disease characterized by progressive loss of articular cartilage, subchondral bone remodeling, and osteophyte formation. It is the most common form of arthritis ^[2].
• Rheumatoid Arthritis (RA): A systemic, autoimmune inflammatory disorder primarily affecting synovial joints, leading to symmetric polyarthritis, joint erosion, and extra-articular manifestations ^[3].
• Gout: An inflammatory arthritis caused by monosodium urate crystal deposition due to hyperuricemia. It presents acutely as a monoarticular, intensely painful "flare" (e.g., first metatarsophalangeal joint) ^[4].
• Pseudogout (Calcium Pyrophosphate Deposition Disease): A crystal-induced arthritis similar to gout but caused by calcium pyrophosphate crystals, often affecting the knee or wrist ^[4].
• Septic Arthritis: A medical emergency involving infection within a joint space. Requires urgent aspiration, broad-spectrum antibiotics, and surgical consultation ^[5].
• Fibromyalgia: A chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, and tender points; often coexists with arthritis but is not inflammatory ^[6].
• Disease-Modifying Antirheumatic Drugs (DMARDs): Medications that slow or halt the progression of inflammatory arthritis (e.g., methotrexate, hydroxychloroquine, biologics) ^[3].

Diagnostic Strategies for Distinguishing Inflammatory vs. Degenerative Arthritis

Distinguishing OA from RA

Key Diagnostic Steps

1. History: Pain location (unilateral/bilateral, symmetric/asymmetric), duration, pattern of stiffness, aggravating/relieving factors, functional limitations, previous trauma, family history.
2. Physical Exam: Inspect for swelling, deformity, erythema, warmth; palpate for tenderness, crepitus; assess range of motion and joint stability; examine extra-articular signs (rheumatoid nodules, skin rashes, psoriatic plaques).
3. Imaging: Plain X-rays (weight-bearing views for knees/hips) are first-line for OA; MRI or ultrasound may be used to evaluate soft tissues or early inflammation.
4. Laboratory Studies: In suspected inflammatory arthritis, order CBC, ESR, CRP, rheumatoid factor (RF), anti-CCP antibodies, and ANA; joint aspiration with crystal analysis and culture is essential for acute monoarticular arthritis ^[5].

Clinical Presentations: Patterns and Red Flags in Arthritis

• OA: Deep, aching joint pain aggravated by use; morning stiffness lasting <30 min; crepitus; bony enlargement (Heberden's nodes at DIP; Bouchard's nodes at PIP).
• RA: Symmetric polyarthritis with warmth, swelling, and tenderness; prolonged morning stiffness; presence of rheumatoid nodules (subcutaneous) in seropositive patients; late-stage deformities (ulnar drift, swan-neck, boutonnière).
• Gout: Sudden onset of severe, throbbing pain, redness, and swelling in a single joint (podagra is classic); possible tophi in chronic cases.
• Septic Arthritis: Acute monoarthritis (most commonly knee), fever (>38°C), joint immobility, and exquisite pain with any motion; joint aspiration shows elevated WBC, positive Gram stain/culture.

Evidence-Based Treatment Protocols for Common Arthritides

Osteoarthritis Management

• Non-Pharmacologic: Weight loss if overweight/obese (target BMI <25), low-impact exercise (walking, swimming, cycling), physical therapy for strengthening and range of motion, use of assistive devices (cane, walker) ^[2].
• Pharmacologic: First-line – acetaminophen (PRN, not exceeding 3000 mg/day) or topical NSAIDs (diclofenac gel) for mild to moderate pain; oral NSAIDs (ibuprofen, naproxen) with gastroprotection if needed; intra-articular corticosteroids for acute flares; hyaluronic acid injections (controversial, may be used after conservative failure).
• Surgical: Total joint arthroplasty (hip or knee) when conservative measures fail and significant disability persists.

Rheumatoid Arthritis Management

• Early, aggressive treatment with DMARDs is critical to prevent joint damage and disability ^[3].
• First-line DMARD: Methotrexate (with folic acid supplementation). Alternatives: sulfasalazine, leflunomide, hydroxychloroquine (for mild disease).
• Biologic DMARDs: TNF-alpha inhibitors (adalimumab, etanercept, infliximab), IL-6 inhibitors (tocilizumab), abatacept, or rituximab for moderate-to-severe disease inadequate response to methotrexate.
• Adjunctive Medications: Short-term low-dose corticosteroids (<10 mg/day prednisone) for flares; NSAIDs for symptom relief.
• Monitoring: Regular labs (CBC, LFTs, creatinine, ESR/CRP) and screening for TB/hepatitis before biologics.

Gout Management

• Acute flare: NSAIDs (indomethacin, naproxen), colchicine, or corticosteroids (oral or intra-articular).
• Chronic urate-lowering therapy: Allopurinol (first-line) or febuxostat; start after acute flare resolves. Check serum urate levels every 2–4 weeks until goal <6 mg/dL ^[4].
• Prophylaxis: Colchicine or low-dose NSAID for first 3–6 months of urate-lowering therapy to prevent flares.
• Lifestyle modifications: Reduce purine-rich foods (red meat, organ meats, shellfish, beer), increase hydration, avoid alcohol and high-fructose sweeteners.

Risk Mitigation: Drug Monitoring and Recognizing Septic Arthritis

• NSAID Risks: GI bleeding, renal impairment, cardiovascular events (especially in older adults). Use lowest effective dose, add PPI if history of GI ulcer, and avoid in patients with advanced CKD (eGFR <30) ^[7].
• Corticosteroid Risks: Weight gain, hyperglycemia, osteoporosis, avascular necrosis, immunosuppression. Use short-term only for flares; avoid long-term use in elderly.
• Methotrexate Toxicity: Hepatotoxicity, myelosuppression, pulmonary fibrosis, teratogenicity. Contraindicated in pregnancy. Monitor LFTs, CBC, and creatinine monthly.
• Biologic DMARDs: Increased risk of serious infections (especially TB, hepatitis B reactivation). Screen for latent TB and HBV prior to initiation.
• Septic Arthritis Red Flags: Fever, exquisite joint pain, inability to bear weight or move joint. Requires urgent aspiration, empiric antibiotics (vancomycin plus ceftriaxone), and surgical drainage ^[5].

Essential Clinical Distinctions for the FNP Exam

• Memorize the key differences between OA and RA – this is a classic “compare and contrast” question.
• Remember the "gelling phenomenon" of OA (pain after inactivity, short-lived stiffness) vs. RA “morning stiffness” lasting >1 hour.
• In acute monoarthritis, always rule out septic arthritis – treat as infected until proven otherwise. Do not rely on fever alone (especially in elderly).
• Gout can mimic infection – aspiration is the gold standard to differentiate.
• Methotrexate is the anchor drug for RA – it is considered first-line DMARD unless contraindicated.
• Avoid long-term narcotics for chronic arthritis pain – focus on non-pharmacologic therapy, acetaminophen, NSAIDs, and appropriate DMARDs.
• For elderly patients with OA, prioritize safety over pain control – risk of falls, GI bleeding, and renal injury. Use topical over oral NSAIDs when possible.
• Know when to refer to rheumatology: Inflammatory arthritis (suspected RA, psoriatic arthritis, lupus), refractory gout, monoarticular crystal arthritis (uncertain diagnosis), or need for biologic therapy.

References

1. Centers for Disease Control and Prevention. Arthritis: Data and Statistics. Updated November 23, 2022. Accessed May 2025. https://www.cdc.gov/cdi/indicator-definitions/arthritis.html
2. Felson DT. Osteoarthritis. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Elsevier; 2020: chap 258. ISBN 978-0-323-53266-2.
3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
4. Ross JJ. Septic arthritis. Infect Dis Clin North Am. 2017;31(1):203–218. https://doi.org/10.1016/j.idc.2016.10.006
5. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547–1555. https://doi.org/10.1001/jama.2014.3266